PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.…
PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026
PROCEPT BioRobotics (NASDAQ: PRCT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 888 employees.
The shares were at 24.70 USD on 20 November 2026, down 21.1% over 52 weeks. Its 52-week range is 16.67 USD to 38.11 USD: the price is 35.2% below the high and 48.2% above the low.
Its market capitalisation is 1.42B USD.
PROCEPT BioRobotics reports return on equity of -26.1%, an operating margin of -34.5% and revenue up 18.0% year over year.
It holds more cash than debt, a net cash position of 141.38M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Hold; their mean price target of 22.75 USD is 7.9% below the current price. The next earnings report is expected on 25 February 2027.